Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 2 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Recs

0
Player Avatar pyupie0216 (28.38) Submitted: 8/18/2010 5:54:40 PM : Underperform Start Price: $32.43 ACOR Score: +51.47

screen

Featured Broker Partners


Advertisement